In male rats with NAFLD, exenatide dose-dependently improved most listed metabolic, hepatic and inflammatory markers versus NAFLD controls.
In plain wordsIn rats with fatty liver, exenatide improved most listed disease markers compared with untreated fatty-liver controls.
- Peptide
- Exenatide (exendin-4)
- Outcome
- MixedComposite metabolic, hepatic and inflammatory marker response
- Study
ratn: not reported in source
Male Wistar rats with high-fat-diet-induced NAFLD- Comparator
- NAFLD control group
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- 10, 20, and 40 μg/kg/day · subcutaneous · 7 weeksAs given in this study (rat).
Source sentences
In a dose-dependent manner, exenatide significantly improved most of the above mentioned markers in comparsion with NAFLD at P≤0.05.
3 context sentences(design, population, supporting numbers)
NAFLD control group showed hyperglycemia, hyperinsulinemia, increased liver enzymes, hypertriglyceridemia, elevated hepatic lipid peroxides, and inflammatory mediators (interlukin 6, nuclear factor-κB, tumor necrosis factor-α and Toll-like receptor4) in addition to hepatic fatty degeneration.
Thirty male Wistar rats were allocated into 6 groups, 5 rats per each group.
Group II: (NAFLD control group), group III: received metformin (60 mg/kg/day, P.O.), group IV-VI: received exenatide (10, 20, and 40 μg/kg/day, S.C.) respectively for 7 weeks.